Mutanome

Transgene and NEC Demonstrate High Accuracy of AI-based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050

Friday, May 15, 2020 - 6:10am

To evaluate the accuracy of the prediction, samples from cancer patients were collected.

Key Points: 
  • To evaluate the accuracy of the prediction, samples from cancer patients were collected.
  • Title of the poster: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
    The abstract can be downloaded on the AACR website.
  • This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC's Neoantigen Prediction System.
  • For more information, visit NEC at https://www.nec.com.For additional information, please also visit NEC Laboratories Europe GmbH at: http://www.neclab.eu

Achilles Therapeutics announces formation of Scientific Advisory Board

Wednesday, May 13, 2020 - 12:00pm

The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.

Key Points: 
  • The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.
  • We are delighted to be working with world-renowned experts who bring deep scientific and medical expertise as we develop the next-generation of truly patient-specific clonal-neoantigen therapies that will harness the immune system to destroy cancer cells, said Dr Iraj Ali, CEO of Achilles Therapeutics.
  • Her research focuses on cancer immune therapies including novel immune checkpoint inhibitors and cancer vaccines to overcome immune tolerance to cancers.
  • Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.

Achilles Therapeutics announces formation of Scientific Advisory Board

Wednesday, May 13, 2020 - 7:00am

The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.

Key Points: 
  • The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.
  • We are delighted to be working with world-renowned experts who bring deep scientific and medical expertise as we develop the next-generation of truly patient-specific clonal-neoantigen therapies that will harness the immune system to destroy cancer cells, said Dr Iraj Ali, CEO of Achilles Therapeutics.
  • Her research focuses on cancer immune therapies including novel immune checkpoint inhibitors and cancer vaccines to overcome immune tolerance to cancers.
  • Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Competitive Landscape and Market Forecast 2035

Thursday, April 23, 2020 - 1:06pm

Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.

Key Points: 
  • Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.
  • Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body's immune system to fight cancer.
  • Click here to know more on Competitive Landscape of Neoantigen-based Personalized Cancer Therapeutic Vaccines.
  • The pipeline of Neoantigen-based Personalized Cancer therapeutic Vaccines appears to be very promising with availability of vaccines in different stages of development.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Competitive Landscape and Market Forecast 2035

Thursday, April 23, 2020 - 1:03pm

Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.

Key Points: 
  • Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.
  • Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body's immune system to fight cancer.
  • Click here to know more on Competitive Landscape of Neoantigen-based Personalized Cancer Therapeutic Vaccines.
  • The pipeline of Neoantigen-based Personalized Cancer therapeutic Vaccines appears to be very promising with availability of vaccines in different stages of development.

Avidea Technologies Utilizes GenScript's Synthesized Neoantigen Peptides for Novel Personalized Cancer Vaccine

Wednesday, January 15, 2020 - 12:30pm

PISCATAWAY, N.J., Jan. 15, 2020 /PRNewswire/ -- GenScript , a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a groundbreaking peptide-based personalized cancer vaccine.

Key Points: 
  • PISCATAWAY, N.J., Jan. 15, 2020 /PRNewswire/ -- GenScript , a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a groundbreaking peptide-based personalized cancer vaccine.
  • Developing and validating SNP-7/8a as a personalized cancer vaccine required synthesis of hundreds of unique neoantigen peptides, which were successfully synthesized by Genscript in support of this work.
  • The publication is particularly timely as personalized cancer vaccines are garnering increasing attention among the scientific and medical community as important components to enabling precision immuno-oncology.
  • To support this work, GenScript synthesized hundreds of challenging neoantigen peptides that were selected to have a wide range of properties, including neoantigen peptides with extremes of net charge and hydrophobicity, which was instrumental to enabling Avidea and NIH scientists to validate the generalizability of the SNP-7/8a platform as a personalized cancer vaccine.

BostonGene Announces Scientific Collaboration with the Vaccine and Immunotherapy Center at Massachusetts General Hospital

Tuesday, January 14, 2020 - 2:00pm

BostonGene Corporation (BostonGene), a biomedical software company, today announced its collaboration with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital.

Key Points: 
  • BostonGene Corporation (BostonGene), a biomedical software company, today announced its collaboration with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital.
  • BostonGene performs a computational analysis of a patient's genomics and transcriptomics data from solid tumors including Lung Cancer and Head and Neck Cancer.
  • The results of this collaboration highlight the powerful advantage of NGS data analysis in comparison to conventional techniques to more fully characterize the tumor.
  • Our collaboration with BostonGene is aimed at understanding the pathogenesis of each persons cancer and ultimately having a positive impact on patient care by enabling personalized cancer treatments, said Mark Poznansky, MD, PhD, at Massachusetts General Hospital.